FrancophonIA/ELRC3.0 huggingface dataset:
English: The applicant has also reviewed the available published clinical trial literature on topical diclofenac which includes a study on effects of Emulgel on Joint Pain (Predel 2012), study on DHEP (Diclofenac hydroxyethylpyrrolidine plaster), Heparin plaster or placebo plaster (Constantino C et al. 2011) and an uncontrolled study on DHEP gel.
Croatian: Podnositelj prijave pregledao je i dostupnu objavljenu literaturu o kliničkim ispitivanjima o diklofenaku za lokalnu primjenu, uključujući ispitivanje o učincima lijeka Emulgel na bol u zglobovima (Predel 2012.), ispitivanje o DHEP-u (zavoj diklofenaka hidroksietilpirolidin), heparinskom zavoju ili placebo zavoju (Constantino C. i dr. 2011.) i nekontrolirano ispitivanje o gelu DHEP.
English: All these studies provide evidence on modest efficacy for authorised topical diclofenac formulations of which the most robust is study Predel 2012 with Emulgel,.
Croatian: Sva ta ispitivanja pružaju dokaze o skromnoj učinkovitosti odobrenih formulacija diklofenaka za lokalnu primjenu, pri čemu najopsežnije dokaze ima ispitivanje lijeka Emulgel (Predel, 2012.).
English: The applicant included a review of the Predel 2013 study [previously pre-publication known as Study 9702SUV] on the efficacy of Spraygel in acute ankle injury.
Croatian: Predel iz 2013. (prethodno izdanje poznato je kao ispitivanje 9702SUV) o učinkovitosti lijeka Spraygel u pogledu akutne ozljede zgloba.
English: Although the strength of the proposed cutaneous spray is 4% as compared to the Emulgel which is 1% or 2%, this difference in the cutaneous spray was designed to deliver a similar amount of diclofenac to local tissues as the Emulgel.
Croatian: Iako jačina predloženog spreja za kožu iznosi 4 % u usporedbi s lijekom Emulgel jačine 1 % ili 2 %, ta razlika u spreju za kožu omogućuje primjenu slične količine diklofenaka na lokalna tkiva kao i kod lijeka Emulgel.
English: The only intra-study comparative data that is available is from study Martin et al. 1997 which indicated that the systemic absorption is comparable for Spraygel and Emulgel, but a conclusion on equivalence - and clinical relevance of systemic absorption - cannot be drawn.
Croatian: Jedini komparativni podatci dostupni su iz ispitivanja koje su proveli Martin i dr. iz 1997. u kojem je pokazano da se sustavna apsorpcija lijekova Spraygel i Emulgel može usporediti, ali nije moguće donijeti zaključak o ekvivalentnosti ni o kliničkoj važnosti sustavne apsorpcije.
English: The CHMP agreed that topical NSAIDs, including Diclofenac Sodium Spray Gel 4 %, have a proven safety record over many more than 10 years, which is supported by their low systemic bioavailability compared to e.g. oral pharmaceutical forms.
Croatian: CHMP se složio s tvrdnjom da NSAID-ovi, uključujući Diclofenac Sodium Spray Gel 4 % imaju dokazani sigurnosni profil već više od 10 godina, a potkrepljuje ga niska sustavna biodostupnost u usporedbi s npr. oralnim farmaceutskim oblicima.
English: The applicant's submissions as part of the referral procedure incorporates literature data and discussions on Quality, Clinical Pharmacology, Clinical Efficacy and Clinical Safety aspects.
Croatian: Podatci koje je podnio podnositelj prijave u okviru postupka upućivanja obuhvaćaju rasprave iz literature o kakvoći, kliničkoj farmakologiji, kliničkoj učinkovitosti i kliničkoj sigurnosti.
English: Most of the data are cross-study comparisons which are affected by different doses and methods and so no robust conclusions can be drawn from these cross-study comparisons.
Croatian: Većina podataka uglavnom su usporedbe iz više ispitivanja te se odnose na različite doze i načine primjene tako da iz njih nije moguće izvući zaključke utemeljene na više ispitivanja.
English: However, the study can be considered supportive of efficacy to infer that Spraygel has beneficial activity in the context of this bibliographic application.
Croatian: Međutim, ovim se ispitivanjem potkrjepljuju podatci o učinkovitosti lijeka Spraygel i njegovom blagotvornom djelovanju u kontekstu ove bibliografske prijave.
English: The Committee considered the available data submitted in support of the use of Diclofenac Sodium Spray Gel 4 % Cutaneous Spray, Solution and associated names , which included a comparison of quality aspects in relation to authorised topical diclofenac products, and literature covering pharmacokinetic (local and systemic) as well as efficacy and safety data.
Croatian: Odbor je u obzir uzeo dostupne podatke dostavljene u izvješću o uporabi lijeka Diclofenac Sodium Spray Gel 4 % za kožnu primjenu i pridruženih naziva, uključujući usporedbu aspekata kvalitete u odnosu na odobrene lijekove s diklofenakom za lokalnu primjenu, kao i literaturu s farmakokinetičkim (lokalnim i sustavim) podacima te podacima o sigurnosti i učinkovitosti.
English: Further as the systemic and topical exposure data of Emulgel is available for comparison to Spraygel, the Marketing Authorisation Holder bridged the efficacy of Emulgel to Spraygel based on a cross-study comparison of the efficacy endpoints, which are however confounded by differences in study methods and populations.
Croatian: Budući da su podatci o sustavnoj i lokalnoj izloženosti lijeka Emulgel dostupni za usporedbu s podatcima za Spraygel, nositelj odobrenja za stavljanje lijeka u promet povezuje učinkovitost lijekova Emulgel i Spraygel na temelju usporedbe iz više ispitivanja krajnjih točki učinkovitosti, no one nisu potpuno jasne zbog različitih metoda i populacija korištenih u ispitivanju.
English: The original application in 2000 under Article 4.8 (a) (II) of Directive 65/65/EEC - bibliographic for new pharmaceutical form and strength, was supported with published literature on efficacy of topical diclofenac as well as data from pharmacokinetics and a clinical study (9702 SUV) of the proposed 4% cutaneous spray formulation.
Croatian: Direktive 65/65/EEZ - bibliografski podatci za novi farmaceutski oblik i jačinu - potkrijepljena je objavljenom literaturom o učinkovitosti diklofenaka za lokalnu primjenu, kao i podatcima iz farmakološkog i kliničkog ispitivanja (9702 SUV) predložene formulacije spreja za kožu jačine 4 %.
English: Nevertheless, it is consistently seen across studies that measurable levels of diclofenac have been reported after application of the spraygel both in systemic exposure and topical exposure (subcutaneous tissue and muscle tissue) at the site of action.
Croatian: Međutim, u ispitivanjima je dosljedno prikazano da su prijavljene mjerljive razine diklofenaka nakon primjene gela u spreju, i kod sustavne i lokalne izloženosti (subkutano tkivo i mišićno tkivo) na mjestu primjene.
English: The defined primary endpoint response, expressed as a decrease in swelling of at least 50% during 10 days of treatment for the ‘Full Analysis Set' (FAS), was reached in 87/97 patients treated with diclofenac spray gel (89.7%) compared to
Croatian: Definirana primarna krajnja točka odgovora, izražena kao smanjenje oteknuća za najmanje 50 % tijekom 10 dana liječenja za „potpuni skup za analizu” (FAS), dosegnuta je u 87/97 bolesnika koji su liječeni gelom u spreju s diklofenakom (89,7 %) u usporedbi sa 74/94 bolesnika liječenih placebom (78,7 %); p = 0,0292 (jednostrano) i p = 0,0467 (dvostrano).
English: Day 60 of the CMDh procedure was on 29 March 2018, and since two Member States raised concerns regarding potential serious risk to public health (PSRPH) related to lack of efficacy for the specific 4% spraygel product and inadequate bridging to literature, in particular with other topical diclofenac formulations (including Voltarol Emulgel) for which it was acknowledged that there was adequate evidence of efficacy and safety, the Reference Member State (UK) triggered on 5 April 2018 a referral under Article 29(4) of Directive 2001/83/EC, requesting the CHMP to assess the impact of the objections raised that constitute a potential serious risk to public health.
Croatian: Budući da su dvije države članice izrazile zabrinutost u pogledu mogućeg ozbiljneog rizika za javno zdravlje u vezi s manjkom učinkovitosti specifičnog lijeka jačine 4 %u obliku gela u spreju i manjkavim upućivanjem na literaturu, posebno u odnosu na druge formulacije diklofenaka za lokalnu primjenu (uključujući Voltarol Emulgel) za koje je poznato da ne postoje odgovarajući dokazi učinkovitosti i sigurnosti, referentna država članica (UK) 5. travnja 2018. pokrenula je postupak upućivanja na temelju članka 29. stavka 4.
English: The Committee, as a consequence, considers that the benefit-risk balance of Diclofenac Sodium Spray Gel 4 % Cutaneous Spray, Solution and associated names is favourable and therefore recommends the granting of the marketing authorisation(s) for the medicinal products referred to in Annex I of the CHMP opinion.
Croatian: Odbor, posljedično, smatra da je omjer koristi i rizika spreja za kožu Diclofenac Sodium Spray Gel 4 % za kožnu primjenu i pridruženih naziva povoljan te stoga preporučuje izdavanje odobrenja za stavljanje u promet lijeka navedenog u Prilogu I. mišljenja CHMP-a.
English: Therefore the CHMP agreed by majority, that the benefit-risk balance of Diclofenac Sodium Spray Gel 4 % is favourable.
Croatian: Stoga je CHMP većinski odlučio da je omjer koristi i rizika za Diclofenac Sodium Spray Gel 4 % povoljan.
English: Overall summary of the scientific evaluation by the CHMP In summary, when taken together the totality of scientific evidence supports that Diclofenac Sodium Spray Gel 4 % has an acceptable safety and efficacy profile.
Croatian: Uglavnom, ukupni znanstveni dokazi govore u prilog tome da lijek Diclofenac Sodium Spray Gel 4 % ima prihvatljivi sigurnosni i djelotvorni profil.
English: Nevertheless, while it is acknowledged that the efficacy of Emulgel cannot be directly attributed to Diclofenac Sodium Spray Gel 4 %, it is also reasonable to infer that Diclofenac Sodium Spray Gel 4 % has a beneficial effect based on the supportive Predel 2013 study, PK comparisons and cross-study comparisons in a similar range as seen for other topical diclofenac products.
Croatian: Štoviše, iako je utvrđeno da se učinkovitost lijeka Emulgel ne može izravno pripisati gelu Diclofenac Sodium Spray Gel 4 %, također je razumno pretpostaviti da Diclofenac Sodium Spray Gel 4 % ima sličan blagotvoran učinak kao i drugi lijekovi s diklofenakom za lokalnu primjenu na temelju ispitivanja
English: In particular their use and substitution for oral and other systemically administered NSAIDS makes a major contribution to patient well-being in view of the available safety data, which supports a markedly lower risk of potentially serious adverse events compared to systemically administered diclofenac containing products.
Croatian: Njihova uporaba i zamjena oralnih i drugih NSAID-ova za sustavnu primjenu uvelike doprinosi dobrobiti bolesnika u pogledu dostupnih podataka o sigurnosti.
English: Annex II Scientific conclusions
Croatian: Cjelokupan sažetak znanstvene ocjene CHMP-a
English: The valid summary of product characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure.
Croatian: Važeći sažetak opisa svojstava lijeka, označavanje i uputa o lijeku su završna verzija postignuta tijekom postupka pod nadzorom Koordinacijske grupe.
English: 12 November, 2012
Croatian: 12. studenog 2012.
English: The safety and efficacy of dapagliflozin in children aged 0 to < 18 years have not yet been established.
Croatian: Sigurnost i djelotvornost dapagliflozina u djece u dobi od 0 < 18 godina još nisu ustanovljene.
English: • Do not take a double dose of Forxiga to make up for a forgotten dose.
Croatian: • Nemojte uzeti dvostruku dozu lijeka Forxiga kako biste nadoknadili zaboravljenu dozu.
English: What you need to know before you take Forxiga
Croatian: Što morate znati prije nego počnete uzimati lijek Forxiga
English: Mean daily insulin dose (IU)
Croatian: Srednja dnevna doza inzulina (IU)
English: • if you are allergic to dapagliflozin or any of the other ingredients of this medicine (listed in section 6).
Croatian: Nemojte uzimati lijek Forxiga: • ako ste alergični na dapagliflozin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
English: The hazard ratio comparing dapagliflozin to comparator was 0.79 (95 % Confidence interval [CI]: 0.58, 1.07), indicating that in this analysis Forxiga is not associated with an increase in cardiovascular risk in patients with type 2 diabetes mellitus.
Croatian: Omjer hazarda kod usporedbe dapagliflozina i usporednog lijeka bio je 0,79 (95% intervala pouzdanosti [CI]: 0,58; 1,07), što ukazuje na činjenicu da se u toj analizi Forxiga ne povezuje s povećanjem kardiovaskularnog rizika u bolesnika sa šećernom bolešću tipa 2.
English: Urine laboratory assessments Due to its mechanism of action, patients taking Forxiga will test positive for glucose in their urine.
Croatian: Zbog mehanizma djelovanja lijeka, bolesnici koji uzimaju lijek Forxiga će imati pozitivan nalaz testa glukoze u mokraći.
English: In a 52-week, active-controlled non-inferiority study (with 52- and 104-week extension periods), Forxiga was evaluated as add-on therapy to metformin compared with a sulphonylurea (glipizide) as add-on therapy to metformin in subjects with inadequate glycaemic control (HbA1c > 6.5 % and ≤ 10 %).
Croatian: U 52-tjednom ispitivanju neinferiornosti, kontroliranom aktivnim lijekom (s produžecima od 52, odnosno 104 tjedna), Forxiga se ocjenjivala pridodana metforminu u usporedbi sa sulfonilurejom pridodanom metforminu u bolesnika u kojih glikemija nije bila dovoljno dobro regulirana (HbA1c > 6,5% i ≤ 10%).
English: Forxiga has not been studied in severe renal impairment (CrCl < 30 ml/min or eGFR < 30 ml/min/1.73 m 2) or end-stage renal disease (ESRD).
Croatian: Forxiga nije ispitana u teškom oštećenju bubrežne funkcije (CrCl < 30 ml/min ili eGFR < 30 ml/min/1,73 m 2) ili terminalnoj fazi bubrežne bolesti.
English: Forxiga is not recommended for use in patients with moderate to severe renal impairment (patients with CrCl < 60 ml/min or eGFR < 60 ml/min/1.73 m2).
Croatian: Primjena lijeka Forxiga ne preporučuje se u bolesnika s umjerenim do teškim oštećenjem bubrežne funkcije (bolesnici u kojih je CrCl < 60 ml/min ili eGFR < 60 ml/min/1,73 m 2).
English: LOCF: Last observation (prior to or on the date of the first insulin up-titration, if needed) carried forward All randomised subjects who took at least one dose of double-blind study medicinal product during the short-term double-blind period Least squares mean adjusted for baseline value and presence of oral glucose-lowering medicinal product p-value < 0.0001 versus placebo + insulin ± oral glucose-lowering medicinal product p-value < 0.05 versus placebo + insulin ± oral glucose-lowering medicinal product Up-titration of insulin regimens (including short-acting, intermediate, and basal insulin) was only allowed if subjects met pre-defined FPG criteria.
Croatian: LOCF: Prijenos posljednjih zabilježenih vrijednosti (prije ili na dan prvog povećanja doze inzulina, ako je potrebno) (Last observation carried forward) Svi randomizirani bolesnici koji su tijekom kratkoročnog dvostruko slijepog razdoblja uzeli barem jednu dozu ispitivanog lijeka u dvostruko slijepom ispitivanju Srednja vrijednost najmanjih kvadrata prilagođena za početnu vrijednost i prisutnost peroralnih lijekova za snižavanje razine glukoze p--vrijednost < 0,0001 u odnosu na placebo + inzulin ± peroralni lijek za snižavanje razine glukoze p--vrijednost < 0,05 u odnosu na placebo + inzulin ± peroralni lijek za snižavanje razine glukoze Povećanje doze inzulina (uključujući kratkodjelujući, srednjedugodjelujući i bazalni inzulin) bilo je dopušteno samo ako su ispitanici zadovoljili unaprijed utvrđene kriterije za FPG (glukoza u plazmi natašte).
English: At 52, 104 and 208 weeks, a significantly lower proportion of subjects in the group treated with dapagliflozin (3.5 %, 4.3 % and 5.0 %, respectively) experienced at least one event of hypoglycaemia compared to the group treated with glipizide (40.8 %, 47.0 % and 50.0 %, respectively).
Croatian: Barem jednu epizodu hipoglikemije imao je značajno manji udio ispitanika u skupini liječenoj dapagliflozinom (3,5% tijekom 52 tjedna, 4,3% tijekom 104 tjedna i 5,0% tijekom 208 tjedana), nego u skupini koja je primala glipizid (40,8% tijekom 52 tjedna, 47% tijekom 104 tjedna i 50,0% tijekom 208 tjedana).
English: Forxiga 5 mg film-coated tablets EU/1/12/795/001 14 film-coated tablets EU/1/12/795/002 28 film-coated tablets EU/1/12/795/003 98 film-coated tablets EU/1/12/795/004 30 x 1 (unit dose) film-coated tablets EU/1/12/795/005 90 x 1 (unit dose) film-coated tablets
Croatian: Forxiga 5 mg filmom obložene tablete EU/1/12/795/001 14 filmom obložene tablete EU/1/12/795/002 28 filmom obložene tablete EU/1/12/795/003 98 filmom obložene tablete EU/1/12/795/004 30 x 1 (jedinična doza) filmom obložene tablete EU/1/12/795/005 90 x 1 (jedinična doza) filmom obložene tablete
English: Forxiga 10 mg film-coated tablets EU/1/12/795/006 14 film-coated tablets EU/1/12/795/007 28 film-coated tablets EU/1/12/795/008 98 film-coated tablets EU/1/12/795/009 30 x 1 (unit dose) film-coated tablets EU/1/12/795/010 90 x 1 (unit dose) film-coated tablets
Croatian: Forxiga 10 mg filmom obložene tablete EU/1/12/795/006 14 filmom obložene tablete EU/1/12/795/007 28 filmom obložene tablete EU/1/12/795/008 98 filmom obložene tablete EU/1/12/795/009 30 x 1 (jedinična doza) filmom obložene tablete EU/1/12/795/010 90 x 1 (jedinična doza) filmom obložene tablete
English: Forxiga 10 mg tablets dapagliflozin
Croatian: Forxiga 10 mg tablete dapagliflozin
English: See section 4.4 Reported in ≥ 2 % of subjects and ≥ 1 % more and at least 3 more subjects treated with dapagliflozin 10 mg compared to placebo.
Croatian: Vidjeti dio 4.4 Prijavljeno u ≥ 2% ispitanika liječenih dapagliflozinom u dozi od 10 mg i ≥ 1% češće te u najmanje 3 ispitanika više nego kod primjene placeba.
English: tablet core: microcrystalline cellulose (E460i), anhydrous lactose (see section 2 ‘Forxiga contains lactose'), crospovidone (E1202), silicon dioxide (E551), magnesium stearate (E470b).
Croatian: “Forxiga sadrži laktozu“), krospovidon (E1202), silicijev dioksid (E551), magnezijev stearat (E470b).
English: Forxiga 5 mg tablets dapagliflozin
Croatian: Forxiga 5 mg tablete dapagliflozin
English: Forxiga 5 mg film-coated tablets
Croatian: Forxiga 5 mg filmom obložene tablete
English: Forxiga 10 mg film-coated tablets
Croatian: Forxiga 10 mg filmom obložene tablete
English: Forxiga 5 mg film-coated tablets Each tablet contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin.
Croatian: Forxiga 5 mg filmom obložene tablete Jedna tableta sadrži 5 mg dapagliflozina u obliku dapagliflozin propandiolhidrata.
English: Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets
Croatian: Forxiga 5 mg filmom obložene tablete Forxiga 10 mg filmom obložene tablete
English: Forxiga 10 mg film-coated tablets dapagliflozin
Croatian: Forxiga 10 mg filmom obložene tablete dapagliflozin
English: EU/1/12/795/008 98 film-coated tablets
Croatian: EU/1/12/795/008 98 filmom obloženih tableta
English: Forxiga 5 mg film-coated tablets dapagliflozin
Croatian: Forxiga 5 mg filmom obložene tablete dapagliflozin
English: Baseline (mean) Change from baseline Difference from placebo c
Croatian: Razlika u odnosu na placebo c
English: inhaler (ABS/PE/PP) 3 inhalers (3 x 60 doses)
Croatian: 3 inhalatora (3 x 60 doza)
English: Treatment is once daily.
Croatian: Daje se jedanput dnevno.
English: This summary was last updated in December 2016.
Croatian: Ovaj sažetak je posljednji put ažuriran u prosincu 2016.
English: This authorisation was based on the authorisation granted to Previcox in 2004 (‘informed consent').
Croatian: Odobrenje se temeljilo na odobrenju izdanom za VMP Previcox 2004. godine („informirani pristanak”).
English: The full EPAR for Equioxx can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za VMP Equioxx nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: Two forms of a medicine are bioequivalent when they produce the same levels of active substance in the body.
Croatian: Dva su oblika lijeka bioekvivalentna kada u tijelu proizvode iste razine djelatne tvari.
English: The dose depends on the bodyweight of the animal except for the tablets which are for horses of 450 to 600 kg bodyweight and where the dose is one tablet.
Croatian: Doza ovisi o tjelesnoj masi životinje, osim u slučaju tableta koje se primjenjuju u konja tjelesne mase od 450 do 600 kg, pri čemu je doza jedna tableta.
English: These are typically mild and resolve without treatment.
Croatian: Te su nuspojave obično blage te se povlače bez liječenja.
English: People should avoid contact of the medicine with eyes and skin and wash their hands after handling the product.
Croatian: Treba izbjegavati dodir VMP-a s očima i kožom i oprati ruke nakon rukovanja proizvodom.
English: The overall duration of treatment depends on the horse's response, but should not exceed 14 days.
Croatian: Trajanje terapije ovisi o reakciji konja na liječenje, no terapija ne smije trajati dulje od 14 dana.
English: Equioxx firocoxib
Croatian: Equioxx firokoksib
English: The withdrawal period for meat from horses treated with Equioxx is 26 days.
Croatian: Razdoblje karencije za meso konja liječenih VMP-om Equioxx iznosi 26 dana.
English: By reducing the production of prostaglandins, Equioxx helps reduce the responses of inflammation, including pain.
Croatian: Smanjivanjem proizvodnje prostaglandina Equioxx pomaže u smanjenju posljedica upale, uključujući bol.
English: The European Commission granted a marketing authorisation valid throughout the EU for Equioxx on 25 June 2008.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za VMP Equioxx na snazi u Europskoj uniji od 25. lipnja 2008.
English: This is a summary of the European public assessment report (EPAR) for Equioxx.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) VMP-a Equioxx.
English: Other information about Equioxx:
Croatian: Ostale informacije o VMP-u Equioxx:
English: The active substance in Equioxx, firocoxib, is a non-steroidal anti-inflammatory drug (NSAID) that belongs to the group of medicines called ‘cyclo-oygenase-s (COX-2) inhibitors' (or Coxibs).
Croatian: Djelatna tvar u VMP-u Equioxx, firokoksib, je nesteroidni protuupalni lijek (NSAID) koji spada u skupinu lijekova naziva „inhibitori ciklooksigenaze-2 (COX-2)” (ili koksibi).
English: Equioxx must not be used at the same time as corticosteroid medicines or other NSAIDs.
Croatian: Equioxx se ne smije primjenjivati istodobno s lijekovima koji sadrže kortikosteroide ili s drugim NSAID-ovima.
English: It blocks the COX-2 enzyme, resulting in a reduction in the production of prostaglandins, substances that are involved in the inflammation process.
Croatian: Onemogućuje djelovanje enzima COX-2, što dovodi do manjeg stvaranja prostaglandina, tvari koje su uključene u upalni proces.
English: The studies showed that Equioxx oral paste given daily for 14 days was as effective as the comparator medicines.
Croatian: Ispitivanja su pokazala da je peroralna pasta Equioxx kada se primjenjuje dnevno u razdoblju od 14 dana jednako učinkovita kao usporedivi lijekovi.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Equioxx's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za veterinarsko-medicinske proizvode (CVMP) pri Agenciji odlučio je da koristi od VMP-a Equioxx nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: It contains the active substance firocoxib.
Croatian: Sadrži djelatnu tvar firokoksib.
English: Why is Equioxx approved?
Croatian: Zašto je Equioxx odobren?
English: This means that the solution for injection and the chewable tablets can be expected to produce similar results to the oral paste.
Croatian: To znači da se može očekivati da otopina za injekciju i tablete za žvakanje daju rezultate slične onima koje daje peroralna pasta.